Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Overview
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Companies Involved in Therapeutics Development
Aeter Zentaris Inc
AstraZeneca Plc
Extend Biosciences Inc
Helsinn Group
Lumos Pharma Inc
Oxeia Biopharmaceuticals Inc
Pfizer Inc
RaQualia Pharma Inc
Tempest Therapeutics Inc
TheraSource LLC
Zeria Pharmaceutical Co Ltd
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Drug Profiles
amorelin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-12861903 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-418 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibutamoren mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
livoletide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
macimorelin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OXE-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-05190457 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00433412 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GHSR for Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Z-505 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Dormant Products
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Discontinued Products
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Product Development Milestones
Featured News & Press Releases
Jun 28, 2021: Lumos Pharma announces OraGrowtH212 trial of LUM-201 in PGHD is open for enrollment
Jun 03, 2021: Aeter Zentaris announces fil settlement of previously disclosed class-action lawsuit
May 17, 2021: Aeter Zentaris announces the start of preclinical development of Macimorelin at The University of Queensland as a potential new treatment option for patients with amyotrophic lateral sclerosis (ALS, Lou Gehrig’s Disease)
May 13, 2021: Aeter Zentaris commences pivotal phase 3 DETECT-trial for the diagnosis of childhood-onset growth hormone deficiency
Apr 27, 2021: Newly released data on three PGHD patients treated with LUM-201 in prior phase 2 study to be presented in Lumos Pharma Key Opinion Leader Webir
Apr 21, 2021: Launch of Adlumiz (amorelin), a Ghrelin Receptor Agonist in Japan
Apr 14, 2021: Lumos Pharma to host key opinion leader event on LUM-201 for the treatment of pediatric growth hormone deficiency
Mar 20, 2021: Data presented at ENDO 2021 differentiate LUM-201 from standard growth hormone secretagogues and further support LUM-201’s potential as a therapeutic for pediatric growth hormone deficiency
Mar 04, 2021: Data supporting use of predictive enrichment markers for Lumos Pharma’s LUM-201 therapy in clinical trials for moderate PGHD published in Jourl of the Endocrine Society
Mar 02, 2021: Lumos Pharma to present poster demonstrating greater GH response to LUM-201 than to standard GH secretagogues in PGHD at the Endocrine Society (ENDO) 2021 annual meeting
Jan 22, 2021: ONO receives a manufacturing and marketing approval of Adlumiz (amorelin), a ghrelin receptor agonist for the treatment of cancer cachexia in Japan
Oct 21, 2020: Oxeia Biopharmaceuticals announces initiation of phase 2 trial for OXE103 for the treatment of concussions
Sep 16, 2020: Aeter Zentaris provides corporate update
Sep 08, 2020: Aeter Zentaris announced presentation of positive results from first pediatric study of Macimorelin at the 22nd European Congress of Endocrinology
Jul 31, 2020: Aeter Zentaris announces continued expansion of intellectual property portfolio for Macimorelin with additiol patent applications
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Aeterna Zentaris Inc, 2021
Pipeline by AstraZeneca Plc, 2021
Pipeline by Extend Biosciences Inc, 2021
Pipeline by Helsinn Group, 2021
Pipeline by Lumos Pharma Inc, 2021
Pipeline by Oxeia Biopharmaceuticals Inc, 2021
Pipeline by Pfizer Inc, 2021
Pipeline by RaQualia Pharma Inc, 2021
Pipeline by Tempest Therapeutics Inc, 2021
Pipeline by TheraSource LLC, 2021
Pipeline by Zeria Pharmaceutical Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Discontinued Products, 2021